51³Ô¹ÏºÚÁÏ

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the formation of a Scientific Advisory Board comprised of industry leaders in neurology and psychiatry, chaired by James E. Galvin, MD, MPH.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Diabetes turns out to be one of the factors in the development of Alzheimer's disease. One of the main features of diabetes - hyperglycemia - is responsible for alzheimer's-like changes.

A study by neuroscientists at the University of Nevada Las Vegas (51³Ô¹ÏºÚÁÏ) showed that chronic hyperglycemia also impairs memory.

University of Nevada, Las Vegas (51³Ô¹ÏºÚÁÏ) neuroscientists report on study findings purportedly strengthening the link between Type 2 diabetes and Alzheimer’s disease.

A team of 51³Ô¹ÏºÚÁÏ neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.

A team of 51³Ô¹ÏºÚÁÏ neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.

A team of 51³Ô¹ÏºÚÁÏ neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.

A team of 51³Ô¹ÏºÚÁÏ neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.

Neuroscientists show that chronic hyperglycemia affects fundamental aspects of memory.

In a new study from the University of Nevada, Las Vegas, researchers confirmed the link between type 2 diabetes and Alzheimer’s disease.

Eisai and Biogen announced that Eisai has initiated a rolling submission to the US Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company’s investigational anti-amyloid beta (Aß) protofibril antibody, for the treatment of early Alzheimer’s disease (early AD).